Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#4462 Clustering of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) using machine learning (ML) and comparison with tumour, node, metastasis (TNM) staging: A population-based study using surveillance, epidemiology, and end results (SEER)

Introduction: TNM 8 is the staging system for GEP-NEN, guiding prognosis and treatment. However, it does not include important prognostic factors such as age, sex, race, and morphology.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, White B, Chandrakumaran K, Ramage J,

Keywords: Clustering, Machine learning, GEP-NEN, TNM Staging, Survival Analysis, SEER,

#4439 Survival of 10,418 lung neuroendocrine tumours after surgical resection: Who needs follow-up and for how long?

Introduction: Surgical resection is the primary treatment for lung neuroendocrine tumours (NETs). The optimal follow-up period is debated in these patients.

Conference:

Presenting Author: El Asmar M

Authors: El Asmar M, Mortagy M, Chandrakumaran K, Ramage J,

Keywords: Lung, Neuroendocrine tumour, survival, surgery, follow-up period,

#4282 A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumours and carcinomas

Introduction: Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Glod J, Magee T, Cooper K, Rivero A,

Keywords: NEN, NEC, NET, ACC, ADC, ADCT-701,

#4016 Factors influencing emergency admissions in patients with neuroendocrine neoplasms (NEN) in England 2016-2017

Introduction: Diagnostic delays in neuroendocrine neoplasms (NEN) are common, with NENs presenting as emergencies in a subset of cases. Emergency presentations (EP) may cause poor outcomes and should be avoided.

Conference:

Presenting Author: El Asmar M

Authors: El Asmar M, Mortagy M, Chandrakumaran K, Srirajaskanthan R, Ramage J,

Keywords: Neuroendocrine tumor, Emergency admission, Survival analysis,